Anti-inflammatory drug shows potential for improved blood formation and treatment of bone damage

Researchers at Dresden University Hospital may have discovered a new therapeutic approach for treating myelodysplastic syndromes (MDS). In a recent study, the team headed by Prof. Manja Wobus and Dr. Katja Sockel demonstrated that the anti-inflammatory drug tasquinimod improves blood formation—which is impaired in MDS—and reduces bone damage in preclinical models.